ES2053676T3 - Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. - Google Patents
Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.Info
- Publication number
- ES2053676T3 ES2053676T3 ES88117833T ES88117833T ES2053676T3 ES 2053676 T3 ES2053676 T3 ES 2053676T3 ES 88117833 T ES88117833 T ES 88117833T ES 88117833 T ES88117833 T ES 88117833T ES 2053676 T3 ES2053676 T3 ES 2053676T3
- Authority
- ES
- Spain
- Prior art keywords
- high ionic
- recombinants
- formulation
- plasma proteins
- ionic force
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
FACTOS ESTABLE VIII Y OTRAS FORMULACIONES DE PROTEINAS PLASMICAS SON SUMINISTRADAS EN MEDIOS DE ALTA FUERZA IONICA LOS CUALES COMPRENDEN: CLORURO DE SODIO, CLORURO DE POTASIO O MEZCLAS DE ELLOS: CLORURO DE CALCIO; E HISTIDINA COMO AGENTE AMORTIGUADOR.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11431487A | 1987-10-29 | 1987-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2053676T3 true ES2053676T3 (es) | 1994-08-01 |
Family
ID=22354487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES88117833T Expired - Lifetime ES2053676T3 (es) | 1987-10-29 | 1988-10-26 | Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0314095B1 (es) |
JP (1) | JP2544968B2 (es) |
AT (1) | ATE83155T1 (es) |
AU (1) | AU622133B2 (es) |
CA (1) | CA1329760C (es) |
DE (1) | DE3876600T2 (es) |
ES (1) | ES2053676T3 (es) |
GR (1) | GR3006506T3 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE148165T1 (de) * | 1989-07-24 | 1997-02-15 | Bayer Ag | Stabilisierung von hochgereinigten proteinen |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
AU670793B2 (en) * | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
US6288030B1 (en) * | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
US5514781A (en) * | 1994-04-11 | 1996-05-07 | Bayer Corporation | Use of azoles as virucidal agents in solutions of biologically active proteins |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US7244824B2 (en) | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7253262B2 (en) | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
KR100564189B1 (ko) * | 1997-04-28 | 2006-03-27 | 일라이 릴리 앤드 캄파니 | 활성화 프로틴c의 가공을 위한 개선된 방법 |
EP1561469A1 (en) * | 1997-04-28 | 2005-08-10 | Eli Lilly & Company | Activated Protein C Formulations |
PT917879E (pt) | 1997-11-22 | 2002-12-31 | Roche Diagnostics Gmbh | Processo melhorado para estabilizacao de proteinas |
CZ307715B6 (cs) | 1999-02-22 | 2019-03-06 | University Of Connecticut | Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu |
US7204981B2 (en) | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
WO2001089558A2 (en) | 2000-05-24 | 2001-11-29 | Eli Lilly And Company | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
EP2283856B1 (en) | 2002-06-21 | 2017-09-20 | Novo Nordisk Health Care AG | Stabilised solid compositions of factor VIIa polypeptides |
CA2492143A1 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
WO2005047323A1 (en) * | 2003-11-10 | 2005-05-26 | Arriva-Prometic Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
TR201809670T4 (tr) | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları. |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
WO2008134310A1 (en) * | 2007-04-26 | 2008-11-06 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
TR201900207T4 (tr) | 2008-11-07 | 2019-02-21 | Baxalta GmbH | Faktör VIII Formülasyonları |
CN103282045A (zh) * | 2010-12-16 | 2013-09-04 | 诺沃—诺迪斯克有限公司 | 因子viii水溶液 |
KR102196009B1 (ko) | 2011-10-25 | 2021-01-04 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
CN104519912A (zh) * | 2012-08-13 | 2015-04-15 | 诺和诺德A/S(股份有限公司) | 液体因子viii制剂 |
CN108348458A (zh) * | 2015-11-05 | 2018-07-31 | 诺和诺德股份有限公司 | Fviii制剂 |
WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3237512A1 (de) * | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
DE3609431A1 (de) * | 1986-03-20 | 1987-09-24 | Biotest Pharma Gmbh | Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates |
-
1988
- 1988-10-25 CA CA000581107A patent/CA1329760C/en not_active Expired - Lifetime
- 1988-10-26 EP EP88117833A patent/EP0314095B1/en not_active Expired - Lifetime
- 1988-10-26 DE DE8888117833T patent/DE3876600T2/de not_active Expired - Lifetime
- 1988-10-26 AT AT88117833T patent/ATE83155T1/de not_active IP Right Cessation
- 1988-10-26 ES ES88117833T patent/ES2053676T3/es not_active Expired - Lifetime
- 1988-10-27 JP JP63269632A patent/JP2544968B2/ja not_active Expired - Lifetime
- 1988-10-28 AU AU24520/88A patent/AU622133B2/en not_active Expired
-
1992
- 1992-12-10 GR GR920402654T patent/GR3006506T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0314095B1 (en) | 1992-12-09 |
JPH01149733A (ja) | 1989-06-12 |
ATE83155T1 (de) | 1992-12-15 |
EP0314095A1 (en) | 1989-05-03 |
DE3876600T2 (de) | 1993-04-15 |
JP2544968B2 (ja) | 1996-10-16 |
DE3876600D1 (de) | 1993-01-21 |
AU622133B2 (en) | 1992-04-02 |
CA1329760C (en) | 1994-05-24 |
AU2452088A (en) | 1989-05-04 |
GR3006506T3 (es) | 1993-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2053676T3 (es) | Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. | |
ES2042693T5 (es) | Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica. | |
DE69729786D1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
NO962791D0 (no) | Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse | |
DK562888D0 (da) | Aminomethyl-oxooxazolidinyl-cycloalkylbenzenderivater, fremstilling deraf, praeparater indeholdende disse og deres anvendelse som antibakterielle midler | |
HUP0100284A2 (hu) | Aktivált protein C készítmények | |
PT758248E (pt) | Formulacoes para o factor ix | |
AU1352483A (en) | Functional human urokinase proteins | |
FI91160B (fi) | Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi | |
DK0482097T3 (da) | Tensidpræparater og fremgangsmåder | |
AU634280B2 (en) | Anticoagulant peptides | |
SE8502540D0 (sv) | Stable dentifrice containing dextranase | |
AU4588089A (en) | Anticoagulant peptides | |
HUT47436A (en) | Process for stabilizing pharmaceutically active proteines in pharmaceutical compositions | |
AU1174588A (en) | Anticonvulsant agents | |
AU2817589A (en) | Amino anthracenediones-bis platinum complexes, useful as antitumoral agents | |
AU6206486A (en) | P-acylaminobenzamides | |
FI960839A0 (fi) | Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa | |
DK0780399T3 (da) | Glucuronyl-arabinarater, fremgangsmåde til fremstilling deraf samt anvendelse af disse produkter | |
NO891926L (no) | Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater. | |
DE69907727D1 (de) | Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen | |
GR880100401A (el) | 8α-ακυλαμινεργολινη,παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν. | |
NO902405D0 (no) | Vevplasminogenaktivatorderivat, dna-sekvens og ekspresjonsplasmid, samt fremgangsmaate for fremstilling av plasmidet. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 314095 Country of ref document: ES |